Site Editor

Thomas Flaig, MD

Advertisement
Advertisement

ESMO 2023: EV-302 Update on Immunotherapy Combination in Advanced Urothelial Cancer

By: Joshua D. Madera, MD
Posted: Wednesday, November 8, 2023

For patients with previously untreated, locally advanced or metastatic urothelial carcinoma, combination immunotherapy with enfortumab vedotin-ejfv and pembrolizumab led to significantly improved clinical outcomes, according to a study presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA6). These findings, along with the manageable safety profile of this combination regimen, support its use as a novel standard of care for this patient population, suggested Thomas B. Powles, MBBS, MRCP, MD, of the Barts Cancer Centre at St. Bartholomew’s Hospital, London, and colleagues.

A total of 886 patients with locally advanced or metastatic urothelial carcinoma were recruited for the study. All were treatment-naive. Patients were randomly assigned to receive combination treatment with enfortumab vedotin and pembrolizumab (n = 442) or chemotherapy (n = 444), and their clinical outcomes were subsequently monitored.

The study findings revealed a significantly prolonged progression-free survival with enfortumab vedotin and pembrolizumab (12.5 months) compared with chemotherapy (6.3 months, hazard ratio [HR] = 0.45). Similarly, the rate of overall survival was increased for patients treated with enfortumab vedotin and pembrolizumab (31.5 months) compared with patients treated with chemotherapy (16.1 months, HR = 0.47). The overall response rates for patients treated with enfortumab vedotin and pembrolizumab and chemotherapy were 67.7% and 44.4%, respectively.

Furthermore, treatment-related adverse events were common regardless of whether patients were treated with enfortumab vedotin and pembrolizumab (55.9%) or chemotherapy (69.5%). The most common adverse events experienced by patients treated with enfortumab vedotin and pembrolizumab included maculopapular rash (7.7%), hyperglycemia (5.0%), and neutropenia (4.8%). The most common treatment-related events experienced by patients treated with chemotherapy were anemia (31.4%), neutropenia (30.0%), and thrombocytopenia (19.4%).

Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.